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PENGENALPASTIAN PENANDA-PENANDA BIO BERPOTENSI BAGI 
KANSER PAYUDARA DI KALANGAN PESAKIT-PESAKIT MALAYSIA 
 
ABSTRAK 
 
Kanser payudara merupakan penyakit barah yang ketiga paling umum di dunia dan 
paling meluas dalam kalangan wanita Malaysia. Pada tahun 2006, sebanyak 3525 kes 
baru kanser payudara telah didaftar dengan Pendaftaran Kanser Kebangsaan 
Malaysia. Protein merupakan komponen yang mengawal aktiviti sel. Melalui 
perbandingan antara protein yang diekspres dalam tisu normal dan kanser, protein 
yang berpotensi untuk mengesan, mengubati, mengawal penyakit payudara boleh 
dikenalpasti. Dalam kajian ini, protein-protein telah diekstrak daripada 25 pasangan 
tisu normal dan kanser daripada pesakit-pesakit payudara jenis infiltrating ductal 
carcinoma(IDC). Protein-protein diasing berdasarkan titik isoelektrik dan berat 
molekul. Tompok-tompok protein dianalisis dan dipencir daripada gel. Selepas itu, 
protein dicerna oleh tripsin untuk menghasilkan tangkaian peptide-peptida yang 
dapat dianalisis oleh LC/MS/MS. Data LC/MS/MS digunakan untuk mengenalpasti 
identiti protein melalui carian database. Dua puluh enam protein telah dikenalpasti 
dalam ekstrak Tris dan 18 protein dalam ekstrak TLB yang mempunyai 
pengekspressan yang berbeza antara tisu-tisu normal and kanser. Fibrinogen beta 
chain merupakan protein kawalaturan-turun (>70%) dalam ekstrak Tris, manakala 
80K protein H precursor, tubulin, beta polypeptide, calreticulin variant and protein 
disulfide-isomerase (PDI) ialah protein-protein kawalaturan-naik (>70%) dalam 
ekstrak TLB. Ujian Western blot dan perwarnaan immunosito bagi PDI dan HSP 60 
dijalankan untuk mengesah dan mengenalpasti lokasi protein pada sel. Keputusan 
xix 
 
menunjukan bahawa PDI berlokasi pada permukaan membran sel MCF-7, T47D dan 
MDA-MB-231. Manakala, HSP 60 hanya berlokasi pada permukaan membran sel 
MCF-7 dan T47D. Protein-protein ekstra selular ini berpotensi untuk dijadikan 
penanda bio bagi rawatan terapi sasaran. Selain itu, kami menyusulkan PDI, heat 
shock protein gp96, HSP60, 80K protein H precursor, calreticulin variant and tubulin, 
beta polypeptide berpotensi sebagai penanda bio bagi kanser payudara. 
Memandangkan kanser ialah sejenis penyakit heterogeneous, penggunaan bersama 
penanda-penanda bio akan member diagnosis yang lebih tepat. Kegunaan penanda-
penanda bio ini boleh dikaji secara lebih dalam pada masa hadapan.     
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IDENTIFICATION OF POTENTIAL BIOMARKERS IN BREAST CANCER 
TISSUES AMONG MALAYSIAN PATIENTS 
 
ABSTRACT 
 
Breast cancer is the third most common cancer worldwide and is the most common 
cancer among Malaysian women. In year 2006, there were 3525 new cases of female 
breast cancer registered with Malaysia National Cancer Registry. Protein is the 
expression component of cells that regulates cellular activity. By comparing healthy 
and cancerous tissues at the protein level, it is possible to identify the potential 
protein targets that can serve to detect, treat, monitor, and for prognosis of breast 
cancer. In this study, proteins were extracted from 25 pairs of breast normal and 
cancerous tissues from patients who suffered from infiltrating ductal carcinoma 
(IDC). These proteins were separated according to their pI‟s and molecular weights. 
The protein spots were analyzed and the protein spots of interest were excised from 
the gel. After that, they were digested with trypsin to produce fragment of peptides 
that can be analyzed using LC/MS/MS. The data obtained from LC/MS/MS analysis 
were subjected to protein database search engine for protein identity determination. 
Twenty-six protein spots from Tris extract and 18 protein spots from TLB extract 
were identified due to their differential expression between cancerous and normal 
tissues. Fibrinogen beta chain was the down-regulated protein (>70%) in Tris extract, 
while 80K protein H precursor, tubulin, beta polypeptide, calreticulin variant and 
protein disulfide-isomerase (PDI) were the up-regulated proteins (>70%) in TLB 
extract. PDI and heat shock protein 60 (HSP60) were selected for Western blot and 
immunocytostaining studies to validate the presence of these proteins and their 
xxi 
 
extracellular location. The results showed that PDI was located on the external 
membrane surface of MCF-7, T47D and MDA-MB-231 cell lines. Meanwhile 
HSP60 was located on the external membrane surface of MCF-7 and T47D cell lines. 
These extracellular surface proteins may serve as potential biomarkers for drug target 
therapy. In addition, PDI, heat shock protein gp96, HSP60, 80K protein H precursor, 
calreticulin variant and tubulin, beta polypeptide were the potential biomarkers in 
breast cancer. As cancer is a heterogeneous disease, the collective use of these 
markers may provide more accurate diagnosis of the disease. The usefulness of these 
proteins as biomarkers for IDC is worth further investigation. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Cancer 
      Cancer is a class of diseases with common feature of uncontrolled cell growth 
(King & Robins, 2006). The growth of cancer cell is different from normal cell 
where the cancer cells grow uncontrollably. The cancer cells are ultimately spread 
throughout the body and interfering with the functions of normal tissues and organs 
in which the cells are life threatening (Cooper & Hausman, 2004). The term “cancer” 
tends to be used differently in experimental and clinical settings. The term “neoplasm” 
refers to new growth and “tumour” refers to abnormal growth. Cancer is more 
precisely defined as invasive and able to metastasise (malignant). In contrast, benign 
growth refers to a localized growth of cells. The benign cells are not always life-
threatening and therefore treatments of these two types of growth are different (King 
& Robins, 2006). However, the benign growth may sometimes lead to malignant 
growth. 
 
The ability of cancer cells to overcome the normal containment mechanisms 
that inhibit cell growth reflects the modification of its membrane that results 
membrane modification in diminishing of cell-cell interactions and the excessive 
production of proteases that facilitate movement through the extracellular matrix. 
Besides that, cancer cells can use chemical messengers to signal normal cells to aid 
in their growth by promoting the development of new blood vessels to ensure an 
adequate supply of essential nutrients, this invasive property is what distinguishes 
cancer cells from normal cells (King & Robins, 2006). Metastasis is the process 
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when cancer cells get into the bloodstream or lymph vessels, and travel to other parts 
of the body. There, the cells begin to grow and form new tumours that replace 
normal tissues (Cooper & Hausman, 2004).  
 
There are more than a hundred distinct types of cancer. Most cancers fall into 
one of three main groups: carcinomas, sarcomas, and leukemias or lymphomas. 
Carcinoma, which made up approximately 90% of human cancers are malignancies 
of epithelial cells. Sarcomas are solid tumors of connective tissues, such as muscle, 
bone, cartilage, and fibrous tissue. Sarcoma is rare in human. Leukemias and 
lymphomas account for approximately 7% of human malignancies, they arise from 
the blood-forming cells and from cells of the immune system, respectively (Cooper 
& Hausman, 2004). 
 
Cancer is one of the major problems in Malaysia (Lim, 2002). In 2006, a total 
of 21,773 cancer cases were diagnosed and registered in the National Cancer 
Registry (NCR) in Peninsular Malaysia. The cases comprises of 9,974 males and 
11,799 females. The Age standardised Incidence Rate (ASR) for all cancers in 2006, 
regardless of gender, was 131.3 per 100,000 population. The ASR among males in 
Peninsular Malaysia was 128.6 per 100,000 population while there was 135.7 per 
100,000 population among female (Omar, 2006). Cancer is more predominant among 
Chinese as compared to Malay and Indian in Peninsular Malaysia. The ASR for 
Chinese male was 148.0 per 100,000 population and for Chinese female was 151.5 
per 100,000 population. For Malay males, the ASR was 94.5 per 100,000 population 
and Malay female was 96.4 per 100,000 population. The ASR of cancer among 
Indian males was 97.4 per 100,000 population and 134.7 per 100,000 population for 
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Indian females (Omar, 2006). The five most common cancers in Peninsular Malaysia 
were breast, colorectal, lung, cervix and nasopharynx (Omar, 2006). Figure 1.1 
shows ten most frequent cancers of Peninsular Malaysia in 2006. 
 Figure 1.1: Ten most frequent cancers in Peninsular Malaysia in 2006  
                                   (Omar, 2006) 
Many factors may increase the likelihood of developing cancer which 
includes radiation (atomic, ultraviolet and X-ray), chemicals (arsenic and chromium, 
carcinogenic in tobacco smoke, aflatoxin from fungus), bacteria and viruses such as 
Helicobacter pylori and Human papillomaviruses (HPVs). The radiation and 
chemicals act by damaging DNA and inducing mutations (Cooper & Hausman, 2004; 
King & Robins, 2006) whereas viruses initiate cancer under conditions not 
completely understood (Cooper & Hausman, 2004). Differences in the incidence of 
cancer around the world usually can be traced to environmental influences (Kumar et 
al, 1992). Geographical distributions and influences of lifestyle, such as diet, 
personal practices, workplace and ambient environment, are the factors that may 
contribute to cancer development (King & Robins, 2006). Figure 1.2 illustrates the 
prevalence of certain cancers in different countries. The most common cancer in  
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United States of America (USA), China and Malaysia were breast and prostate 
cancer,  stomach and esophagus, colorectal and breast cancer, respectively (King & 
Robins, 2006; Omar, 2006). 
Figure 1.2: Comparison of the five most common cancers in the USA, China 
and Malaysia (King & Robins, 2006; Omar, 2006) 
               
      Diet is a major determinant of human carcinogenesis, which reflects the 
effects of complex chemicals mixture. There is increasing debate about the 
carcinogenicity of food additives, artificial sweeteners, and containing pesticides 
(King & Robins, 2006; Kumar et al., 1992). Gastric carcinomas may relate to 
endogenous synthesis of carcinogens or promoters from diet. Nitrosamines and 
nitrosamides are believed to be carcinogens because they have been clearly shown to 
induce gastric cancer in animals. These compounds can be formed in the body from 
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nitrates and amines or amides derived from digested proteins. The sources of nitrites 
include sodium nitrate, a food preservative (Kumar et al., 1992).  
 
1.2     Breast Cancer 
Breast cancer is a malignant tumour that derives from the cells of breast. It is 
commonly found in women, but men can also get breast cancer. The ratio of male 
carcinoma to female carcinoma is 1:125 (Kumar et al., 1992). Breast cancer is the 
third most common cancer worldwide and is the most common cancer among 
Malaysian women (McPherson et al., 2000b);(Hisham and Yip, 2004). In 2006, 
breast cancer was reported to be the most common cancer among female and also the 
most prevalence cancer among population in Peninsular Malaysia regardless of 
gender. There were 3525 female breast cancer cases registered in NCR, accounted 
for 16.5% of all cancer cases registered. The incidence of breast cancer varies among 
the ethnics in Peninsular Malaysia. According to the record in NCR for 2006, 
Chinese have the highest ASR among the three major ethnics, for example, 46.4 per 
100,000 population followed by Indian and Malay, respectively with the ASR of 38.1 
per 100,000 population and 30.4 per 100,000 respectively (Omar, 2006). 
 
1.2.1    Types of Breast Cancer 
There are many types of breast cancer, but some of the types are very rare. 
The common types of breast cancer include ductal carcinoma in situ (DCIS), lobular 
carcinoma in situ (LCIS), invasive ductal carcinoma (IDC) and invasive lobular 
carcinoma (ILC), while the less common types of breast cancer are inflammatory 
breast cancer (IBC), medullary carcinoma, Paget's disease of the breast, tubular 
carcinoma, phylloides tumour, metaplastic carcinoma, sarcoma, micropapillary 
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carcinoma and adenoid cystic carcinoma. Sometimes, a breast tumour can be a mix 
of more than one types or a mixture of invasive and in situ cancer.   
Below are the elaborations of some common types of breast cancer.  
Figure 1.3 Range of ductal carcinoma in situ  
(http://www.breastcancer.org/pictures/types/) 
Ductal carcinoma in situ (DCIS) refers to abnormal cell growth in the lining 
milk duct. It is confined to the walls of the ducts and has not spread into the tissue of 
the breast. Figure 1.3 shows range of ductal carcinoma in situ. This is an early-stage 
breast cancer. Almost all women with DCIS can be successfully treated. However, it 
may eventually develop into invasive breast cancer if left untreated. 
 
Lobular carcinoma in situ (LCIS) begins in the milk-making glands (lobules) 
without invading to the surrounding breast tissue. It is not a true cancer, but having 
LCIS increases a woman's risk of getting cancer later. Women who have LCIS are 
more likely to develop invasive lobular breast.  
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Invasive (or infiltrating) ductal carcinoma (IDC) is the most common breast 
cancer that accounts for 75% of breast carcinoma. It starts in a milk passage (a duct), 
breaks through the wall of the duct, and invades the tissue of the breast. The cancer 
cells may remain localized or it may be able to spread (metastasize) to other parts of 
the body through bloodstream or lymphatic system.  
 
Invasive lobular carcinoma (ILC) starts in the milk-producing lobule, invades 
to the surrounding breast tissue and can metastasize. ILC is harder to be detected as it 
is less likely to appear on a mammogram and patients might not be able to detect a 
breast lump. Patients may perceive only a general thickening or feel some different 
in the breast tissue.  
 
Inflammatory breast cancer (IBC) is uncommon but aggressive type of 
invasive breast cancer that accounts for about 1% to 3% of all breast cancers. IBC 
makes the skin of the breast becomes red, swollen and feels warm.  The skin looks 
thick and pitted something like an orange peel. The breast may get bigger, hard, 
tender, or itchy. Medullary carcinoma is a specific type of invasive breast cancer in 
which the tumour‟s borders are clearly defined, the cancer cells are large, and 
immune system cells are present around the border of the tumour. Mucinous (colloid) 
carcinoma is a type of invasive breast cancer, the cancer cells produce mucus and 
grow into a jelly-like tumour. The tissues are extremely soft, bulky, gray-blue masses 
consist of gelatin. Paget's disease of the breast is rare type of breast cancer that 
affects nipple, and skin surrounding the nipple (areola). Tubular carcinoma gets its 
name from the appearance of the cancer cells under a microscope. Though it is an 
invasive breast cancer, the prognosis is more favourable than invasive ductal 
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carcinoma or invasive lobular carcinoma. Phylloides tumour is a large, bulky tumour. 
phylloides tumours develop in the connective tissue of the breast. The prognosis for a 
phylloides tumour is uncertain. If the tumour cannot be removed, it will be difficult 
to treat. Metaplastic carcinoma tends to remain localized and contains several 
different types of cells that are not typically seen in other forms of breast cancer. 
Sarcoma is a tumour that develops in the connective tissue of the breast, which is 
usually cancerous (malignant). Micropapillary carcinoma is an aggressive invasive 
breast cancer, often spreading to the lymph nodes even when they were very small. 
Adenoid cystic carcinoma is characterized by a large, local tumour. It is an invasive 
but slow-growing type of breast cancer and is unlikely to spread. 
 
1.2.2     Breast Cancer Risk Factor 
Several factors have been identified as potentially responsible for increasing 
breast cancer risk, although their mechanisms of action are unclear (McPherson et al., 
2000b). These factors are: 
a) Previous history of  breast cancer. 
b) Increasing age-estimated 64% of women diagnosed with cancer are over 55 of age.  
c) Early menarche (age 12 and younger) starting menarche at age 11 or earlier is 
considered an established breast cancer risk factor, and starting menarche at age 15 
or older is considered an established protective in risk (Kelsey & Bernstein, 1996). 
d) Late menopause (age 55 and older). Each one-year delay in the onset of 
menopause is associated with a 3% increase risk (Collaborative Group on Hormonal 
Factors in Breast Cancer, 1997). This may be due to the proliferative response of 
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breast epithelial cells to estrogen through the estrogens‟ receptor. (Roses & Giuliano, 
2005). 
e) Nulliparity at age 40 years. Women who have their first birth before age of 20 
have 30% lower risk compare to women with their first birth after the age of 35 
(Ewertz et al., 1990).  
f)  Obesity in postmenopausal women. 
g) Hormone replacement therapy. The Women‟s Health Initiative study found an 
increased risk of breast (cancer ratio 1.26) in women who are on hormone 
replacement therapy combined with estrogen and progestin given in a continuous 
manner (Women‟s Health Initiative Investigators, 2002). 
h) Family history. Women with family history of breast cancer are at increased risk, 
especially those that having first-degree relative with breast cancer increase risk by 
80%.  
i) Evidence of specific genetic susceptibility (such as carriage of BRCA1, BRCA2 or 
BRCA3). BRCA1 and BRCA2 are tumor suppressor genes. When they are mutated, 
cancer is more likely to develop because they no longer cause cells to die at the right 
time.  
 
Some studies have shown that the public are not aware of the risk factor for 
breast cancer by being exposed to some incorrect information. The knowledge of risk 
factors and perception of personal risk are important for motivating people to prevent, 
detect and manage disease as early as possible (Washbrook, 2006). Therefore, it is 
important that accurate information is communicated by physicians and the media. 
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1.2.3     Breast Cancer Treatment 
1.2.3.1 Surgery 
The primary aim of surgery is to remove the entire tumour and metastases in 
regional lymphatic (King & Robins, 2006). Surgery can be conservative (removing 
the lump or a segment of the breast only) or may be in the form of a mastectomy 
(removing the whole breast) (McPherson et al., 2000a). Breast conservation surgery 
followed by radiotherapy is an appropriate method of primary therapy for the 
majority of women with stage I or II breast cancer. It is preferable because it 
provides survival equipment to total mastectomy and axillary clearance while 
preserving the breast (McPherson et al., 2000b) 
 
1.2.3.2 Radiotherapy 
Radiation therapy plays an important role in the curative treatment of breast 
cancer. After conservative surgery, radiation of breast reduces the risk of local 
recurrence rate and possibly prolongs survivals (Stevens, 2005). Radiotherapy uses 
high doses of radiation to kill cancer cells by causing irreparable double-stranded 
DNA breaks (King and Robins, 2006, Hall and Giaccia, 1995) The cell cannot divide 
when it enters mitosis, and cell death occurs (Hall and Giaccia, 1995). Radiation 
therapy will cause side effects, the most common acute effects are fatigue, erythema, 
edema and hyperpigmentation (Stevens, 2005).  
 
1.2.3.3  Chemotherapy 
Chemotherapy uses cytotoxic drugs that disrupt the cell cycle, thus causing 
the death of proliferating cells (King & Robins, 2006). For breast cancer, 
chemotherapy drugs are given intravenously (directly into a vein) or orally (by 
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mouth). Once the drugs enter the bloodstream, they travel to all parts of the body in 
order to reach cancer cells that may have spread beyond the breast. Hence, 
chemotherapy is considered a "systemic" form of breast cancer treatment. For late 
stage disease, chemotherapy is used to control the growth rate of the tumour and to 
downsize the bulk of the disease. Therefore, chemotherapy may also help to control 
symptoms, prolong survival and improve the quality of life. 
 
1.2.3.4 Hormone Therapy 
Hormone or anti-hormone treatment is only given to patients whose cancer 
cells are positive to oestrogen or progesterone receptors. Determination of hormone 
receptor status [estrogen (ER) and progesterone receptor (PR)] has become standard 
practice in the management of invasive breast cancers. It is useful as a prognostic and 
predictive factor (Bauer et al., 2007). By blocking these receptors, the growth of the 
cancer cells can be curtailed. Drugs such as Tamoxifen and the new generation of 
aromatase inhibitors may help to control cancer for many years after primary 
treatment. 
 
Tamoxifen is the standard drug for endocrine therapy in patients with 
estradiol and progesterone receptor positive breast cancer. It is a drug taken orally in 
tablet, interferes with the activity of estrogen. Estrogen can promote the development 
of breast cancer. Tamoxifen works against the effects of estrogen on the cells. It is 
often called an antiestrogen or a SERM (Selective Estrogen Receptor Modulator). 
Tamoxifen has been used to treat patients (men and women) with early-stage breast 
cancer, as well as those with metastatic breast cancer for more than 30 years. 
Tamoxifen has serious side effects, such as blood clots, strokes, uterine cancer, and 
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cataracts. The most common side effects are hot flashes and vaginal discharge. The 
clinical studies of tamoxifen therapy in postmenopausal breast cancer patients 
showed that tamoxifen reduced the incidence of tumours in the second breast but 
increased the risk of endometrial carcinomas (Fornander et al., 1991) 
 
1.2.3.5 Drug Targeted Therapy 
Approximately 25% to 30% of human metastatic breast cancers over-express 
the human epidermal growth factor receptor 2 (HER-2). Overexpression of HER-2 is 
a significant predictor of reduced survival and shorter time to relapse (Slamon et al., 
1987, Huston and Osborne, 2005). This is because these tumours tend to grow faster 
and are more likely to metastase than tumours that do not overexpress HER-2. Thus, 
HER-2 has become an important therapeutic target for this subtype of breast cancer. 
When breast cancer was diagnosed, HER-2 status is routinely assessed by either 
immunohistochemical (IHC) analysis of HER-2 protein expression or fluorescent in 
situ hybridization (FISH) analysis of HER-2 gene copy number in breast tumour 
biopsy (Sauter et al., 2009). The presence of HER-2 overexpression is a predictive 
factor that may indicate success with the use of trastuzumab (Herceptin) (Huston & 
Osborne, 2005) 
 
Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody 
targeted against an extracellular region of the HER-2 receptor, it was approved by 
the FDA in 1998. The initial clinical trials of trastuzumab as a single agent in HER2-
over-expressing metastatic breast cancer demonstrated response rates ranging from 
12% to 34% for a median duration of 9 months (Vogel et al., 2002).  
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1.3 Cancer Biomarker  
Biomarkers are biochemical substrates that are indicators of physiologic state 
and also development during a disease process (Srinivas et al., 2002). Cancer 
biomarker can be classified into cellular and humoral markers. Cellular markers are 
associated with cancer cells; they can provide prognostic information and 
information are for the selection of the optimal drugs or a specific therapeutic plan 
for systemic treatment. (Hunt et al., 2001) D‟Arcy et al., 2006). Humoral cancer 
markers are characterized by their appearance in body fluids, for examples urine, 
blood and body fluid. These markers can be released on tumour disintegration or 
may be secreted by tumours (D‟Arcy et al., 2006).They are also useful in the early 
detection of cancer, especially in asymptomatic people who are at high risk for 
cancer development (Hunt et al., 2001).  
 
Biomarkers are important tools for detection, diagnosis, treatment, 
monitoring, and prognosis of diseases (Srinivas et al., 2002). Cancer biomarkers can 
be divided into three categories: diagnostic (screening) biomarkers, prognostic 
biomarkers and stratification biomarkers. Diagnostic markers are used to detect a 
given type of cancer in an individual. Prognostic biomarkers are commonly used 
when the disease status has been established. They can be used to predict the course 
of disease and its recurrence. Therefore, they indicate the aggressiveness of the 
therapy. Stratification biomarkers serve to predict the likely response to drug (based 
on DNA) before starting a treatment. They classify an individual as “responders” or 
“nonresponder”. Such prediction is important in designing clinical drug trials in 
order to define an intended use for the drug under investigation (Hamdan, 2007).  
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1.3.1     Currently Available Breast Cancer Biomarkers 
There are a few markers for breast cancer. But only two serum markers were 
approved by the Food and Drug Administration (FDA) for monitoring treatment of 
advanced breast cancer or recurrence, these markers are MUC-1 (CA27.29 and 
CA15-3) and carcinoembryonic antigen (CEA) (Kirmiz et al., 2007).  
 
MUC1 mucins are expressed physiologically at the luminal surface of 
glandular epithelia. The expression of MUC1 mucin is usually up-regulated in breast 
cancer and high amount of the protein is released into the blood stream of breast 
cancer patients (Gender et al., 1991); Graves et al., 1998). Family members of MUC-1-
gene include, MCA, BRMA CA549, CA27.29 and CA15-3. CA15-3 is effective in 
evaluating the clinical course of patients being treated for metastatic disease. Serum 
level of CA15-3 is related to tumour size. Several reports suggested that CA27.29 is 
more sensitive but less specific than CA15-3 (Diamandis et al., 2002)  
 
Carcinoembryonic antigen (CEA) is a glycoprotein present in the serum of 
cancer patients that can be detected using radioimmunoassay or enzyme-linked 
immunosorbent assay (Levenson, 2007). Several studies have reported that the 
probability of finding rising level of CEA in patients who were clinically detectable 
with metastatic breast cancer is between 15% to 68% (Hayes et al., 1991). The 
clinical value of CEA detection is limited due to high false-positive rate detected in 
normal populations (Levenson, 2007), the false positive rates is range from 10% to 
27% (Daniel, 2005). CEA main application is in gastrointestinal cancers, especially 
in colorectal malignancy. It is a very useful marker for the early detection of liver 
metastasis in patients with diagnosed with colorectal cancer (Duffy, 2006).  
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Early detection of breast cancer increases the survival rate of the patient 
(Levenson, 2007). However, early symptoms of breast cancer are sometimes absent 
or not recognized. It is often detected in an advanced stage of progression and 
untreatable by the time the cancer is finally diagnosed (Kirmiz et al., 2007). Thus, a 
reliable biomarker is needed to rule out breast cancer in the early state. Unfortunately, 
current available tumour markers are lack of the specificity and sensitivity to be use 
in early detection (Kirmiz et al., 2007; D‟Arcy et al., 2006). 
 
HER-2/neu (c-erbB-2) protein is over expressed in about 20% to 30% of 
invasive breast carcinomas (Lipton, 2005). HER-2 belongs to type I transmembrane 
tyrosine kinase receptor family. HER-2 is an important regulator of cell growth and 
differentiation during embryogenesis and for mammary development during puberty. 
Deregulation of HER-2 signalling in mammary cells promotes breast tumourigenesis 
(Nahta et al., 2009). Two HER2-targeted therapies are approved by the United States 
Food and Drug Administration (FDA) for treatment of HER2-overexpressing 
metastatic breast cancer, namely Trastuzumab (Herceptin) and Lapatinib (Tykerb). 
 
CA-125 is a useful serum marker for monitoring ovarian cancer patients and 
possibly for prediction of the patient‟s response to therapy, but it has insufficient 
sensitivity for the diagnosis of the disease (Bast et al., 2005). Serum CA-125 is lack 
of specificity, it has been shown to be elevated in various form of cancer including, 
ovarian, pancreatic, breast, colon, lung and endometrial carcinoma (Bast, 2003). It is 
commonly agreed that CA-125 is lack both sensitivity and specificity as a marker for 
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early stage disease (stage I and II). However, the specificity can be improved by 
combining CA-125 with various forms of sonography (Hamdan, 2007). 
 
1.4 Proteomics 
Proteomics is a study of the proteome, the protein complement of the genome. 
The terms “proteome” and “proteomics” were introduced by Marc Wilkins and 
colleagues in early 1990s (Liebler, 2002). Proteomics is a branch of functional 
genomics (Palzkill, 2002), the large-scale study of proteins, particularly their 
structure and functions, including detection, identification, measurement of their 
concentration, characterization of modification, characterization of protein-protein 
interaction and regulation (Xiao et al., 2008). The proteome is the end product of 
genome. The proteome is a highly dynamic entity and differs from cell to cell (Xiao 
et al., 2008), while genome is comparatively static (Rabilloud & Humphery-Smith, 
2000). The proteome in cells is constantly changing through its biochemical 
interactions with the genome and the surrounding environment, physiological state of 
the cell (e.g. position in the cell cycle), stress, drug administration, health and disease 
(Rabilloud & Humphery-Smith, 2000). In addition, some proteins may be expressed 
during very short periods of time in the life of an individual, while others may be 
continually expressed (Xiao et al., 2008) 
 
Proteomic technologies allow the identification of the protein changes caused 
by the disease process in a relatively accurate manner (Srinivas et al., 2002).The 
proteome contains all of the gene products that represent the functional output of a 
cell rather than nucleic acids that are derived from an individual‟s full genetic code 
(Palzkill, 2002). This makes proteomics a promising tool for characterizing cells and 
17 
 
tissues of interest and for biomarker discovery (Xiao et al., 2008). Protein analysis is 
considerably more challenging than DNA/RNA-based analyses. DNA is composed 
of only four different nucleotides, while proteins are composed of at least 20 
unmodified and a lot of modified amino acids. Thus the physiochemical 
characteristics of proteins vary considerably. Besides that, expression levels of 
protein cover an extremely large range, and many proteins undergo a myriad of co- 
and postranslational modifications, including phosphorylation, acetylation, sulfation, 
glycosylation and etc. These posttranslational modifications are adding to the 
complexity of protein analysis (Jolles & Jornvall, 2000). 
  
Proteomics directly analyze protein expression at the post-translational level, 
it permits the qualitative and quantitative assessment of a broad-spectrum of proteins 
that can be related to specific cellular responses (Alaiya et al., 2005; Xiao et al., 
2003; Xiao et al., 2005). Qualitative proteomics experiments or protein expression 
mapping aims to study changes in protein expression under different physiologically 
relevant conditions (Ong et al., 2003; Xiao et al., 2008). For clinical applications, 
this may help to discover differences between healthy and diseased patients (Xiao et 
al., 2008). On the other hand, quantitative proteomics not only provides lists of 
identified proteins but also the quantitative information for all proteins in a sample 
(Mann, 1999; Ong & Monn, 2005). Mass spectrometry (MS)-based quantitative 
proteomics has become an increasingly popular approach to study changes in protein 
abundances and diversity in biological samples (Xiao et al., 2008).  
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1.4.1 Proteomics in the Development of Cancer Biomarkers 
It has been estimated that only 2% of human diseases are resulted from single 
gene defects. For remaining 98% of human diseases, epigenetic and environmental 
factors are taken into accounts that affect both the etiology and the severity of the 
affliction (Montreuil et al., 1996). Therefore, cancer biomarker discovery strategies 
that target on protein expressions are becoming increasingly popular because the 
proteomic approaches characterize both the modified or unmodified proteins that are 
involved in cancer progression (Srinivas et al., 2002). In recent years, the emerging 
technologies in the field of genomics and proteomics have led to the discovery of a 
great number of cancer biomarker candidates (Pritzker, 2002). Unfortunately, very 
few of these biomarkers have been validated and approved for prognostic and 
diagnostic purpose (Polanksi & Anderson, 2006). 
 
1.5 Proteomics Tools 
A proteomic analysis from tissues involved a few steps which include 
extraction of proteins from tissue matrix, separation of the protein mixture and 
qualitative and quantitative analysis of the protein by mass spectrometric analysis 
spectrometric analysis, each of these steps are explain as below. 
 
1.5.1 Sequential Protein Extraction 
Protein extraction from tissues and cells is perhaps the most critical step in 
proteomic studies because this step influences protein yield, biological activity and 
the structural integrity of the specific target protein (Simpson, 2003). The sequential 
extraction procedure is based on protein solubility in Tris buffer for the initial 
removal of highly soluble protein, whereas proteins from the insoluble pellet are then 
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extracted with thiourea lysis buffer (TLB), a stringent buffer which contains 8M 
Urea, Thiourea and CHAPS. The sequential extraction buffer can aid in the 
visualization of a greater percentage of the proteome for a complex cell or tissue 
(Cordwell et al., 2000; Molloy et al., 1998).  
 
1.5.1.1 Tris Extraction Buffer 
Tris [tris(hydroxymethyl)aminomethane] is widely used in biochemistry and 
molecular biology as a buffer (Gomori, 1955). Tris is slightly basic with a pKa of 
8.08 (Bates & Pinching, 1949) which makes it suitable for studies in biological 
systems as well as pH control in vitro (Bates et al., 1978; Nahas, 1961). It is used at a 
low concentration of 40 mM to solubilize aqueous soluble proteins (Molloy et al., 
1998; Santoni et al., 2000). 
 
1.5.1.2 Thiourea Lysis Buffer (TLB) 
Thiourea lysis buffer (TLB) modified from Rabilloud (1998) consis of urea, 
thiourea, CHAPS, DTT and carrier ampholyte. Urea and thiourea are chaotropic 
agents which alter all the solvent parameters, exert profound effects on all types of 
interactions function (Herskovits et al., 1970). For example, by changing the 
hydrogen bond structure of the solvent, chaotropes disrupt hydrogen bonds and 
hydrophobic interactions both between and within proteins (Herskovits et al., 1970); 
Rabilloud et al., 1997). When chaotropic agents are used at high concentrations, it 
disrupts protein secondary structure and bring into solution, proteins that are not 
otherwise soluble (Rabilloud et al., 1997).  
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CHAPS, a zwitterionic detergent also disrupt hydrophobic interactions 
between and within proteins and are particularly useful in solubilizing the insoluble 
proteins. Normally neutral or zwitterionic detergents are used in 2-D electrophoresis 
sample preparation, because they are most compatible with subsequent IEF 
separation. Carrier ampholytes are low molecular mass components with both amino 
and carboxyl groups (Monribot & Boucherie, 2000). The presence of carrier 
ampholytes is required to prevent proteins from interacting with each other ionically, 
but without disturbing the pH gradient or interfering with electrophoresis. 
 
1.5.2 2D Gel Electrophoresis 
 Two-dimensional electrophoresis is a powerful proteomic tool which 
combines two dimensions of protein analysis, isoelectric focusing (IEF) and 
polyacrylamide gel electrophoresis (PAGE) for separation of complex protein 
mixtures. It utilizes the principal that all proteins in an electric field migrate at a 
speed that is dependent on their conformation, size, and electric charge (Simpson, 
2003). In the first dimension, the proteins are separated according to net charge or 
isoelectric point (pI), isoelectric focusing (IEF) is done in a polyacrylamide gel with 
a pH gradient.  
 
1.5.2.1 Isoelectric Focusing (IEF)  
Proteins are amphoteric molecules; they are either a positive, negative, or 
zero net charge, depending on the pH of their surroundings. The isoelectric point (pI) 
of a protein is the pH value of the protein‟s surroundings at which the protein has a 
zero net charge. A protein carries a net negative charge when pH values is above its 
pI, while the protein carries a net positive charge at the pH values below the pI. IEF 
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manipulate advantage of this phenomenon (Simpson, 2003). When introduced into 
an electric field, a protein molecule will migrate according to its surface charge. A 
positively charged molecule will gradually loose positive charge and gain negative 
charge through deprotonation of carboxyl or amino functional groups. Eventually, it 
will stops when it reaches its pI (Righetti, 1983). 
 
1.5.2.2 SDS-PAGE 
SDS-PAGE is a method of separating proteins on the basis of their molecular 
weight. The separation is done on SDS polyacrylamide gels (Fichmann & 
Westermeier, 1998). SDS is anionic surfactant that binds to proteins according to a 
constant weight ratio of 1.4g SDS per gram of protein, independent of the nature of 
the protein (Reynolds & Tanford, 1970). The bound of SDS gives the proteins a net 
negative charge per unit mass. SDS disrupts hydrogen bonds, blocks hydrophobic 
interactions, and unfolds the protein, thus eliminating secondary and tertiary 
structures. Reducing agents such as DTT or 2-mercaptoethanol can be added in the 
presence of SDS to break the disulfide bridges and therefore unfold the protein 
completely. There is a linear relationship between the logarithm of the molecular 
mass of the protein and relative migration distance of SDS-polypeptide micelle 
(Laemmli, 1970; Weber & Osborne, 1969) 
  
1.5.3 Liquid Chromatography Mass Spectrometry 
1.5.3.1 Reversed-phased high-performance Liquid Chromatography  
Reversed-phase chromatography separates molecules based on their 
reversible interaction with the hydrophobic surface of a chromatographic medium. It 
is very useful for the separation of protein and peptides. Since the mid 1980s, 
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reversed-phase chromatography has been widely used for the separation of proteins 
on both analytical and preperative scales. However, reversed-phase chromatography 
is not recommended for protein purification if recovery and return of correct tertiary 
structure are required, because many proteins are irreversibly denatured in the 
presence of organic solvents (Simpson, 2003) 
 
The mobile phase in reversed-phase chromatography is an aqueous solution, 
which dissolves the sample and equilibrates the column. Gradient elution allows the 
separation of a complex mixture component that exhibits a broad range of receptivity 
in a single run. The more hydrophobic the solute, the higher is the affinity of the 
solute to the stationary phase and therefore the greater is its retention time. As a 
result, molecules with different equilibrium constants elute at different times and are 
separated (Kastner, 2000). The order of the protein desorption is based on their 
relative hydrophobicity, least hydrophobic proteins elute first, followed by more 
hydrophobic proteins. Because the functional groups on the column support are 
hydrophobic in nature, the elution of protein and peptide from the column requires 
organic solvents and other additives for elution (Simpson, 2003). Due to the retention 
mechanism, a small change in concentration of the organic eluent component can 
dramatically affect retention of peptides and proteins (Kastner, 2000). 
 
1.5.3.2 Mass Spectrometry 
Mass spectrometry is an analytical technique that measures the masses of 
individual molecules and atoms. It consists of three major elements: an ion source, 
mass analyzer and a detector. Mass spectrometers are capable of forming, separating, 
and detecting molecular ion based on their mass-to-charge ratio (m/z) (Simpson, 
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2003). The first essential step in mass spectrometry analysis is to convert the analyte 
molecules into gas-phase ions because the motion of ions can be manipulated and 
detected. The excess energy transferred to the molecule during the ionization leads to 
fragmentation. Then, a mass analyzer separates these molecular ions and their 
charged fragments according to their mass-to-charge ratio (m/z). After that, a 
detector will detect the ion current due to these mass-separated ions and display a 
mass spectrum. Ions from colliding or interacting with other ions, each of these steps 
is carried out under high vacuum (Dass, 2001). 
 
There are only two ionization modes relevant to proteomics, namely MALDI 
and ESI (Roepstorff, 1997). ESI is an atmospheric pressure ionization technique 
applicable to a wide range of liquid matrix compounds (Dass, 2001). Charged ions 
from molecules are formed by electrospray when a solution containing the sample 
enters the ESI source through a flow stream. In the presence of a strong electrical 
field, a fine spray of charged droplets is created from the solution through a small-
diameter needle. A flow of hot-bath gas, usually nitrogen is added to assist in the 
evaporation of the solvent from those charged droplets. The ions are then transferred 
from the atmospheric pressure region to the high-vacumm region of mass analyzer 
for further analysis. All sample ions are stripped off the solvent molecules before 
enter into a mass analyzer (Dass, 2001; Simpson, 2003). ESI ionization forms 
multiple charge states of ions from a single precursor. Composition and pH of the 
electrospray solvent, as well as the chemical nature of the analyte will influence the 
charging of the peptides. ESI is widely used, due to its continuous-flow operation, 
tolerance to different types of solvent, acceptance of wide solvent flow rates, and 
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ability to generate intact multiply charged ions from electrically charged liquid 
droplets (Dole et al., 1968).   
 
After the ionization, the peptide ions are ejected to the gas phase. These ions 
are then drawn into MS which operates under vacuum, ions are trapped by a radio 
frequency trapping field. A small amount of helium gas is used to collisionally cools 
ions and forces them into the center of the ion trap. Ions above a certain minimum 
m/z remain trapped, cycling in a sinusoidal motion. The magnitude of the RF voltage 
determines the frequency and motion of the ions in the trap. The RF voltage is 
ramped up linearly to generate a mass spectrum. When a small voltage is applied 
across the two endcap electrodes, it causes ions of successive m/z values to become 
unstable and to be ejected axially from the trap. This process is termed resonance 
ejection. As ions are ejected from the trap they are detected by an off-axis conversion 
dynode with an electron multiplier detector (Corthals et al., 2000).  
 
1.6 Western Blotting 
Western Blotting combines the resolution of gel electrophoresis with the 
specificity of immunochemical detection (Harlow, 1999). It is a powerful tool to 
detect one or more antigens in a mixture (Hames et al. 1990) and characterize a 
variety of proteins, especially those of low abundance. Western blotting is 
particularly useful when dealing with antigens that are insoluble, difficult to label or 
easily degraded (Harlow, 1999). Protein blotting or western blotting involves transfer 
of proteins to an immobilizing membrane. Electrophoretic transfer of resolved 
proteins from a polyacrylamide gel to a nitrocellulose or polyvinylidene difluoride 
(PVDF) sheet is the most widely used blotting method. It uses the driving force of an 
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electric field to elute proteins from gels to immobilize them on a matrix (Gravel, 
2002). This method is fast, efficient and maintains the high resolution of the protein 
pattern (Garfin and Bers, 1982). There are two types of electrophoretic transfer 
methods: wet transfer or semi-dry transfer.  
 
For semidry blotting, the gel and membrane are sandwiched horizontally 
between two stacks of filter papers that were buffered-wetted and directly contact 
with two closely spaced solid-plate electrodes. The name semidry refers to the 
limited amount of buffer that is confined to the stacks of filter paper. Semidry 
blotting requires considerably less buffer than the tank method (Gravel, 2002). Wet 
transfer devices are typically composed of a tank that holds the transfer buffer and 
one or more cassettes that slightly compress the fragile polyacrylamide gel against 
the transfer membrane and hold it perpendicular to the electrical field generated by 
the unit (Lee and Nilsen-Hamilton, 2001). 
 
Once transferred to a membrane, proteins are more readily and equally 
accessible to various ligands than they were in the gel (Gravel, 2002). A blocking 
buffer containing bovine serum albumin (BSA) or non-fat skimmed milk is added to 
saturate unoccupied protein-binding sites in order to prevent non-specific binding of 
the antibody to the membrane. This is done before adding the primary antibody. 
After that, the location of the specific antigens is determined using a labeled primary 
antibody or an unlabeled primary antibody, followed by a labeled secondary 
antibody. The secondary antibody that is specific to the primary antibody can be 
radiolabeled or covalently conjugated to an enzyme. Finally, a substrate is added to 
